Hepatoprotective effect of Anacyclus pyrethrum Linn. against antitubercular drug-induced hepatotoxicity in SD rats.
BACKGROUND
Traditional remedies employ herbal drugs for the treatment of liver ailments and hepatoprotection. Thus, the present study was designed to evaluate the hepatoprotective effect of "extract of Anacyclus pyrethrum Linn" (APE) against antitubercular drug-induced hepatotoxicity in rats.


METHODS
Group I rats (normal control) received vehicle (1 % CMC), while group II rats (hepatotoxic control) isoniazid (INH) plus rifampicin (RIF) each 50 mg/kg/day po, for 28 days. Group III, IV and V rats were administered with APE 200, APE 400 and silymarin 100 mg/kg/day po, respectively, for 28 days. Concurrently, hepatotoxicity was tried to induce by coadministration of INH and RIF each 50 mg/kg/day po for 28 days in group III, IV and V rats. After 24 h of the last dosing, blood was obtained under light anesthesia and the rats were killed. Hepatoprotective effect was assessed by liver weight, relative liver weight and biochemical parameters such as serum glutamate oxaloacetate transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), serum bilirubin, cholesterol, total protein and albumin levels.


RESULTS
Group IV rats showed significant (p<0.01) decrease in SGPT, SGOT, ALP, LDH, cholesterol, serum bilirubin, liver weight and relative liver weight Levels, while significant (p<0.01) increase in final body weight (b. wt.), total protein and albumin levels as compared to group II rats. Hepatoprotective effect of APE 400 mg/kg/day was comparable to that of silymarin 100 mg/kg/day and the hepatic marker levels were also restored. Hepatoprotective effect of APE was well supported by the histopathological results.


CONCLUSIONS
Hydroalcoholic APE root possesses hepatoprotective activity as it exhibited the protective effect against INH plus RIF-induced hepatotoxicity in rats.
Afreen
A
Usmani
Md
M
Mujahid
Mohammad
M
Khushtar
Hefazat H
HH
Siddiqui
Md Azizur
MA
Rahman
D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase; D000818:Animals; D000995:Antitubercular Agents / Q000009:adverse effects*; D001219:Aspartate Aminotransferases / Q000097:blood; D019659:Asteraceae; D001663:Bilirubin / Q000097:blood; D001798:Blood Proteins / Q000378:metabolism; D056486:Chemical and Drug Induced Liver Injury / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood; D007538:Isoniazid / Q000009:adverse effects*; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008099:Liver / Q000187:drug effects* / Q000201:enzymology; D008297:Male; D009929:Organ Size; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use; D017207:Rats, Sprague-Dawley; D012293:Rifampin / Q000009:adverse effects*
D000995:Antitubercular Agents; D001798:Blood Proteins; D010936:Plant Extracts; D002784:Cholesterol; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D001663:Bilirubin; D007538:Isoniazid; D012293:Rifampin